Auna S.A. (AUNA) is an integrated Latin American healthcare company — not an ETF — that operates hospitals, clinics, and prepaid oncology and general health plans across Peru, Colombia, and Mexico. It is headquartered in Luxembourg and listed on the NYSE in March 2024.
Three recently updated, individually attributable price targets form the basis of the $7.00 central target. Jefferies analyst Antonio Pedro Cardoso initiated coverage with a Buy rating and a $9.00 target in January 2026. HSBC analyst Raj Sinha upgraded the stock to Buy from Hold in January 2026 with a $6.90 target. JPMorgan analyst Joseph Giordano moved in the opposite direction, cutting the target to $5.00 from $6.00 in May 2026 while keeping a Neutral rating. The arithmetic mean of these three figures is $6.97, rounded to $7.00. Third-party aggregators tracking five to seven analysts show a similar average of about $6.97–$6.99 and a range of roughly $5.00 to $9.00. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The divergence is meaningful. The cautious view, led by JPMorgan, argues that Auna's consolidated growth profile is underwhelming and that leverage will remain elevated. The more constructive view, from Jefferies and HSBC, sees a reset valuation and long-term growth optionality from the integrated oncology network as worth paying for. No consensus guarantees a move to any target.
Shares traded near $4.61 in mid-November 2026, toward the lower end of a 52-week range of roughly $4.09 to $6.70. The company carries a market capitalization of roughly $380–400 million and generated trailing revenue near $1.37 billion, but net income and EPS (earnings per share) remain depressed, leaving a very high P/E (price-to-earnings) ratio on trailing earnings.
Reaching $7.00 from $4.61 requires about a 52% advance — a very large move that would first require the stock to recover its prior trading range and clear former highs. In its most recent quarter reported in August 2026, Auna delivered revenue of about $362.9 million, slightly above consensus, but EPS of $0.15 missed the roughly $0.26 estimate. A sustained climb toward $7.00 would likely depend on a return to consistent earnings growth and clearer evidence that the Mexico business is scaling profitably.
The bullish case rests on valuation and franchise quality. Auna operates a vertically integrated network of roughly 30-plus healthcare facilities and serves about 1.4 million health-plan members, with a focus on high-complexity care such as oncology. After a decline of more than 40% from early-2025 levels, bulls argue the shares already discount much of the near-term execution risk.
Trailing revenue has been growing at a high-single-digit pace, and HSBC's upgrade to Buy signals confidence that the stock is undervalued. Jefferies' $9.00 initiation similarly reflects a view that the integrated model can compound over time as new facilities mature. Deleveraging, even gradual, would also support a re-rating, since a high debt-to-equity ratio of roughly 1.6 is a key reason the stock trades at a discount.
The principal obstacle is financial and operational. JPMorgan's downgrade to Neutral and its cut to a $5.00 target cited a slower-than-expected ramp-up in Mexico, a less compelling consolidated growth profile, and leverage that is expected to remain elevated. An EPS miss in the most recent quarter reinforced concerns that profitability has yet to stabilize.
Other risks include currency and macroeconomic volatility across Peru, Colombia, and Mexico, competitive pressure in health insurance, and thin margins. As a small-cap stock with modest trading volume, AUNA can also be subject to sharp price swings that are not fully explained by fundamentals.
The chart shows a stock in a longer-term downtrend. The 52-week low near $4.09 is the key support level to watch, while the prior highs near $6.70 act as a meaningful resistance level on any recovery. The $5.00 mark, coinciding with JPMorgan's target, is an intermediate psychological level that price would need to reclaim before the $7.00 objective becomes relevant. A sustained move above the former trading range would be required to change the technical structure from defensive to constructive.
Analyst price targets typically reflect a research horizon of about 12 months, though the specific time frame is not always stated and varies by firm. Investors weighing the $7.00 stock forecast should watch quarterly earnings and guidance, particularly any evidence that Mexico is scaling and that margins are improving. Debt reduction, analyst revisions, currency moves in the company's operating countries, and any changes to the leverage profile are also central to the market outlook.
The question of whether AUNA can reach $7.00 comes down to whether execution improves faster than the cautious camp expects. The target reflects a rough average of analyst views — a wide $5.00 to $9.00 range that captures genuine disagreement about Mexico and leverage — and implies about a 52% move from current levels, which is very large. The strongest supports are the reset valuation, the integrated oncology franchise, and Buy ratings from Jefferies and HSBC. The principal obstacles are elevated debt, weak near-term profitability, and the slower Mexico ramp flagged by JPMorgan. Investors should monitor earnings, deleveraging progress, and analyst revisions rather than treat the $7.00 figure as a guarantee.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than replacing your own judgment, the tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently. For anyone tracking a volatile name like AUNA, automated signal generation can complement fundamental research. Consider exploring AI Daily Buy/Sell Signals to see how AI-driven monitoring fits into your workflow.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Indicator for AUNA moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 18 similar instances when the indicator left oversold territory. In 16 of the 18 cases the stock moved higher. This puts the odds of a move higher at 89%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 28 of 36 cases where AUNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on AUNA as a result. In 44 of 57 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for AUNA just turned positive on November 17, 2026. Looking at past instances where AUNA's MACD turned positive, the stock continued to rise in 17 of 22 cases over the following month. The odds of a continued upward trend are 77%.
Following a +3.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUNA advanced for three days, in 75 of 121 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
AUNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
AUNA moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AUNA crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
The 50-day moving average for AUNA moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. AUNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.186) is normal, around the industry mean (204.532). P/E Ratio (21.273) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.289) is also within normal values, averaging (2.688).
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HospitalNursingManagement